StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Revance Therapeutics presently has an average rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $3.65 on Monday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $6.65. The company has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The firm has a fifty day moving average price of $3.65 and a 200 day moving average price of $3.77.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds have recently modified their holdings of the business. Natixis acquired a new stake in Revance Therapeutics during the 4th quarter worth $31,000. Two Sigma Securities LLC acquired a new stake in shares of Revance Therapeutics during the fourth quarter worth about $35,000. Alpine Global Management LLC purchased a new position in shares of Revance Therapeutics during the fourth quarter worth about $37,000. RPO LLC purchased a new stake in Revance Therapeutics during the 4th quarter valued at approximately $55,000. Finally, Fairfax Financial Holdings Ltd. Can purchased a new stake in Revance Therapeutics during the 4th quarter valued at approximately $64,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.